<DOC>
	<DOCNO>NCT02541669</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics safety single- multiple-dose TAK-491 healthy Chinese participant .</brief_summary>
	<brief_title>A Single- Multiple-Dose Study Pharmacokinetics TAK-491 Healthy Chinese Subjects</brief_title>
	<detailed_description>The drug test study call TAK-491 . TAK-491 test treat people hypertension . This study look pharmacokinetics TAK-491 Chinese people take TAK-491 . The study enroll approximately 64 participant . The first 16 enrolled subject randomly assign ( chance , like flip coin ) 1 2 treatment group : - TAK-491 40 mg - TAK-491 80 mg All participant ask take 1 tablet time Day 1 Day 4 10 study . The follow 48 randomized participant randomly assign ( chance , like flip coin ) 1 3 treatment group : - TAK-491 40 mg - TAK-491 80 mg - TAK-491 placebo All participants ask take two tablet time Day 1 Day 4 10 study . This single-center trial conduct China . The overall time participate study approximately 52 day . Participants admit clinic first 12 day , contact telephone 14 day last dose study drug follow-up assessment .</detailed_description>
	<criteria>1 . Is capable understand comply protocol requirement . 2 . The participant , applicable , legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is healthy adult male female Chinese descent . 4 . Is age 18 45 year , inclusive , time informed consent first study medication dose . 5 . Has body mass index ( BMI ) great equal ( &gt; = ) 19.0 kilogram per square millimeter ( kg/m^2 ) less ( &lt; ) 24.0 kg/m^2 , inclusive Screening . 6 . Has clinical laboratory evaluation ( include clinical chemistry [ fast least 8 hour screen assessment ] , hematology , complete urinalysis ) within reference range test laboratory , unless result deem investigator clinically significant Screening Checkin ( Day 1 ) . 7 . Is willing refrain strenuous exercise , 72 hour Checkin ( Day1 ) Final Visit . 8 . A female childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 30 day last dose study drug . 1 . Has receive investigational compound within 30 day prior Screening . 2 . Has receive TAK491 previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 4 . Has history uncontrolled , clinically significant manifestation metabolic ( include diabetes mellitus , hypercholesterolemia , dyslipidemia ) , endocrine , hematologic , pulmonary , cardiovascular , gastrointestinal , neurological , rheumatologic , skin subcutaneous tissue disorder , infectious , hepatic , renal , urologic , immunologic , psychiatric mood disorder ( include past history suicide attempt ) , history lactose intolerance , may impact ability subject participate potentially confound study result . 5 . Has know hypersensitivity component formulation TAK491 AII inhibitor related compound . 6 . Has positive urine drug result drug abuse breath alcohol test Screening Checkin ( Day 1 ) . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 8 . Has take exclude medication , supplement , food product . 9 . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 10 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis frequent [ per week ] occurrence heartburn , surgical intervention [ example , cholecystectomy ] ) . 11 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 12 . Has positive test result antiHIV , antiHCV antibody , HBsAg Screening.. 13 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) . Cotinine test positive Screening Checkin ( Day 1 ) . 14 . Has poor peripheral venous access . 15 . Has donate lose 450 milliliter ( mL ) blood volume ( include plasmapheresis ) , transfusion blood product within 30 day prior Day 1 . 16 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator . 17 . Has abnormal Screening Checkin ( Day 1 ) laboratory value suggest clinically significant underlying disease subject follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great ( &gt; ) 1.5 time upper limit normal . 18 . Has hemoglobin value &lt; 12 gram per deciliter ( g/dL ) Screening . 19 . Has systolic blood pressure &lt; 110 &gt; =160 millimeter Mercury ( mmHg ) diastolic blood pressure &lt; 60 &gt; =100 mmHg Screening Checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>